pulmonary%20arterial%20hypertension
PULMONARY ARTERIAL HYPERTENSION
Pulmonary arterial hypertension is a syndrome resulting from restricted flow through the pulmonary arterial circulation resulting in increased pulmonary vascular resistance and ultimately leading to right heart failure.
It is a part of the spectrum of pulmonary hypertension, which is hemodynamic and pathophysiological condition defined as an increase in mean pulmonary arterial pressure ≥25 mmHg at rest.
Typical symptoms include progressive dyspnea on exertion, palpitations, fatigue, weakness, angina, syncope and abdominal distention.

Surgical Intervention

Balloon Atrial Septostomy (BAS)

  • Several experimental & clinical observations suggest that an atrial defect may be of benefit in the setting of pulmonary hypertension (PH) as it would allow right to left shunting which increases systemic output
    • This would increase systemic arterial oxygen saturation
    • It also decompresses the right atrium & ventricle therefore decreasing signs & symptoms of right heart failure
  • At present, indications for BAS are:
    • Patients who are in World Health Organization functional class (WHO FC) IV with severe syncope &/or right heart failure despite all available medical treatments
    • Palliative bridge to lung transplantation
    • Sole treatment modality when other options are not available
    • Considered in pulmonary arterial hypertension (PAH) associated with surgically corrected congenital hear disease (CHD), connective tissue disease, distal chronic thromboembolic pulmonary hypertension (CTEPH), pulmonary veno-occlusive disease & pulmonary capillary hemangiomatosis
    • May be considered before severe hemodynamic compromise & end-organ dysfunction occur
  • Should be performed only at institutions with significant procedural & clinical experience
  • Avoided in patients with a baseline mean right atrial pressure (RAP) of 20 mmHg & O2 saturation at rest of <85% on room air

Transplantation

  • There is no agreement on the optimal type of transplantation for patients with PAH, whether single lung, double lung or combined heart & lung
  • Indicated in PAH patients when they have an unacceptable response to PAH therapies seen in FC III or IV
  • Due to lack of effective medical therapeutic regimen, patients with pulmonary veno-occlusive disease & pulmonary capillary hemangiomatosis should be candidates for transplantation at diagnosis
  • Survival rates in PAH patients undergoing transplant: 66% at 1 year, 57% at 3 years, 47% at 5 years & 27% at 10 years
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
15 Aug 2017
New drug applications approved by US FDA as of 1 - 15 August 2017 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
04 Aug 2017
Chronic obstructive pulmonary disease (COPD) is the fourth cause of global mortality, with experts predicting a potential future rise in the prevalence rates of COPD. 
11 May 2016

In conjunction with World Asthma Day which falls on 3rd May 2016, MIMS Doctor speaks to a renowned respiratory medicine specialist, Dato' Dr. Hj Abdul Razak Abdul Muttalif, regarding the chronic airway disease.

Pearl Toh, 22 May 2016
Asthma patients on salmeterol, a long-acting beta-agonist (LABA), plus fluticasone inhaled corticosteroid (ICS) combination therapy did not have a greater risk of serious asthma-related events compared with patients receiving fluticasone alone, according to the recent AUSTRI* study.